Sylvie Laquerre

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Jessie Villanueva, Adina Vultur, John Tayu Lee et al. · Cancer Cell · 2010 · 1.2K citations · Full text

Medicine, Cancer Biology, Oncology +13

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by <i>NRAS</i> or <i>MEK</i> Mutations

James Greger, Stephen D. Eastman, Vivian Zhang et al. · Molecular Cancer Therapeutics · 2012 · 374 citations

Medicine, Oncology, Pharmacology +16

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy Perera, Eleonora Jovcheva, Laurence Mévellec et al. · Molecular Cancer Therapeutics · 2017 · 340 citations · Full text

Medicine, Oncology, Pharmacology +17

Heparan Sulfate Proteoglycan Binding by Herpes Simplex Virus Type 1 Glycoproteins B and C, Which Differ in Their Contributions to Virus Attachment, Penetration, and Cell-to-Cell Spread

Sylvie Laquerre, Rafaela Argnani, Dina Anderson et al. · Journal of Virology · 1998 · 288 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17